Connor Clark & Lunn Investment Management Ltd. Acquires 201,945 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 789.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 227,512 shares of the medical research company’s stock after buying an additional 201,945 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in IQVIA were worth $44,708,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Private Trust Co. NA boosted its stake in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after buying an additional 47 shares during the period. Pine Valley Investments Ltd Liability Co boosted its stake in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares during the period. Howard Capital Management Inc. lifted its stake in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after purchasing an additional 54 shares during the last quarter. Huntington National Bank lifted its stake in IQVIA by 7.4% during the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after purchasing an additional 56 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after purchasing an additional 56 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.1 %

Shares of NYSE:IQV opened at $185.47 on Thursday. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $261.72. The company has a market cap of $32.70 billion, a PE ratio of 24.73, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock’s 50-day moving average is $197.14 and its 200 day moving average is $211.59.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Barclays dropped their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Finally, Stephens started coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.